Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity

• Eduardo Zatarain-Nicolás ^[1] ; Pilar Martín ^[2] ; Iván Márquez Rodas ^[1] ; Juan Virizuela ^[7] ; Ana Martín García ^[3] ; Cristina Mitroi ^[4] ; Juan Cosín Sales ^[8] ; Vivencio Barrios ^[8] ; Fátima Sánchez-Cabo ^[2] ; Borja Ibañez ^[5] ; Javier de Castro Carpeño ^[6] ; Teresa López Fernández ^[6]
  1. [1] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  2. [2] Centro Nacional de Investigaciones Cardiovasculares Carlos III

     Centro Nacional de Investigaciones Cardiovasculares Carlos III

     Madrid, España

     
  3. [3] Hospital Universitario de Salamanca

     Hospital Universitario de Salamanca

     Salamanca, España

     
  4. [4] Hospital Universitario Puerta de Hierro

     Hospital Universitario Puerta de Hierro

     Madrid, España

     
  5. [5] Fundación Jiménez Díaz

     Fundación Jiménez Díaz

     Madrid, España

     
  6. [6] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  7. [7] Departamento de Oncología Médica, Hospital Universitario Virgen de la Macarena, Sevilla, España
  8. [8] Agencia de Investigación de la Sociedad Española de Cardiología (AISEC), Madrid, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 25, Nº. 11 (November), 2023, págs. 3073-3085
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Immune checkpoint inhibitors (ICI) have changed the prognosis of many tumors. However, concerning associated cardiotoxicity has been reported. Little is known about the real-life incidence-specific surveillance protocols or the translational correlation between the underlying mechanisms and the clinical presentation of ICI-induced cardiotoxicity. The lack of data from prospective studies led us to review the current knowledge and to present the creation of the Spanish Immunotherapy Registry of Cardiovascular Toxicity (SIR-CVT), a prospective registry of patients receiving ICI that aims to examine the role of hsa-miR-Chr8:96, (a specific serum biomarker of myocarditis) in the early diagnosis of ICI-induced myocarditis. An exhaustive prospective cardiac imaging study will be performed before and during the first 12 months of treatment. The correlation between clinical, imaging, and immunologic parameters may improve our understanding of ICI-induced cardiotoxicity and enable simpler surveillance protocols. We assess ICI-induced cardiovascular toxicity and describe the rationale of the SIR-CVT.